Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nezam H Afdhal

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
International Journal of Hepatology|January 26, 2024
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility StudyMichael P Curry, Edward Tam, Caitlin Schneider, et al.
Biophysical Journal|August 31, 2002
A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systemsWen Guo, Volker Kurze, Thomas Huber, et al.
The American Journal of Gastroenterology|August 26, 2015
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient ElastographyElliot B Tapper, Neil Sengupta, M G Myriam Hunink, et al.
Biomacromolecules|March 9, 2004
Interaction of mucin with cholesterol enriched vesicles: role of mucin structural domainsNezam H Afdhal, Xingxiang Cao, Rama Bansil, et al.
Biomacromolecules|November 15, 2005
Atomic force microscopy reveals aggregation of gastric mucin at low pHZhenning Hong, Bernard Chasan, Rama Bansil, et al.
Journal of Hepatology|October 27, 2011
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosisAndrés Cárdenas, Pere Ginès, Paul Marotta, et al.
Hepatology Communications|December 31, 2021
Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLDJoana Vieira Barbosa, Scott Milligan, Andrew Frick, et al.
Gastroenterology|April 28, 2012
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitisMiroslaw Kornek, Michael Lynch, Shruti H Mehta, et al.
Scandinavian Journal of Gastroenterology|October 22, 2008
Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosisAndres Cardenas, Robert Lowe, Sangik Oh, et al.
Journal of Managed Care & Specialty Pharmacy|June 9, 2021
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational studyMichael P Curry, Steven L Flamm, Scott Milligan, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
International Journal of Hepatology|January 26, 2024
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility StudyMichael P Curry, Edward Tam, Caitlin Schneider, et al.
Biophysical Journal|August 31, 2002
A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systemsWen Guo, Volker Kurze, Thomas Huber, et al.
The American Journal of Gastroenterology|August 26, 2015
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient ElastographyElliot B Tapper, Neil Sengupta, M G Myriam Hunink, et al.
Biomacromolecules|March 9, 2004
Interaction of mucin with cholesterol enriched vesicles: role of mucin structural domainsNezam H Afdhal, Xingxiang Cao, Rama Bansil, et al.
Biomacromolecules|November 15, 2005
Atomic force microscopy reveals aggregation of gastric mucin at low pHZhenning Hong, Bernard Chasan, Rama Bansil, et al.
Journal of Hepatology|October 27, 2011
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosisAndrés Cárdenas, Pere Ginès, Paul Marotta, et al.
Hepatology Communications|December 31, 2021
Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLDJoana Vieira Barbosa, Scott Milligan, Andrew Frick, et al.
Gastroenterology|April 28, 2012
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitisMiroslaw Kornek, Michael Lynch, Shruti H Mehta, et al.
Scandinavian Journal of Gastroenterology|October 22, 2008
Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosisAndres Cardenas, Robert Lowe, Sangik Oh, et al.
Journal of Managed Care & Specialty Pharmacy|June 9, 2021
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational studyMichael P Curry, Steven L Flamm, Scott Milligan, et al.
Pageof 12